Kodiak Sciences Statistics
Total Valuation
Kodiak Sciences has a market cap or net worth of $2.26 billion. The enterprise value is $2.15 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kodiak Sciences has 62.44 million shares outstanding. The number of shares has increased by 5.40% in one year.
| Current Share Class | 62.44M |
| Shares Outstanding | 62.44M |
| Shares Change (YoY) | +5.40% |
| Shares Change (QoQ) | +13.64% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 66.82% |
| Float | 39.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 20.70 |
| P/TBV Ratio | 20.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.50.
| Current Ratio | 3.54 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -208.80% and return on invested capital (ROIC) is -85.98%.
| Return on Equity (ROE) | -208.80% |
| Return on Assets (ROA) | -49.06% |
| Return on Invested Capital (ROIC) | -85.98% |
| Return on Capital Employed (ROCE) | -92.42% |
| Weighted Average Cost of Capital (WACC) | 16.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.77M |
| Employee Count | 130 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +929.70% in the last 52 weeks. The beta is 2.32, so Kodiak Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.32 |
| 52-Week Price Change | +929.70% |
| 50-Day Moving Average | 37.93 |
| 200-Day Moving Average | 24.15 |
| Relative Strength Index (RSI) | 42.29 |
| Average Volume (20 Days) | 604,294 |
Short Selling Information
The latest short interest is 10.25 million, so 16.41% of the outstanding shares have been sold short.
| Short Interest | 10.25M |
| Short Previous Month | 10.32M |
| Short % of Shares Out | 16.41% |
| Short % of Float | 26.09% |
| Short Ratio (days to cover) | 9.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -237.00M |
| Pretax Income | -230.66M |
| Net Income | -230.66M |
| EBITDA | -219.17M |
| EBIT | -237.00M |
| Earnings Per Share (EPS) | -$4.16 |
Full Income StatementBalance Sheet
The company has $169.53 million in cash and $55.99 million in debt, with a net cash position of $113.54 million or $1.82 per share.
| Cash & Cash Equivalents | 169.53M |
| Total Debt | 55.99M |
| Net Cash | 113.54M |
| Net Cash Per Share | $1.82 |
| Equity (Book Value) | 112.10M |
| Book Value Per Share | 1.81 |
| Working Capital | 125.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$146.94 million and capital expenditures -$1.18 million, giving a free cash flow of -$148.12 million.
| Operating Cash Flow | -146.94M |
| Capital Expenditures | -1.18M |
| Depreciation & Amortization | 17.83M |
| Net Borrowing | n/a |
| Free Cash Flow | -148.12M |
| FCF Per Share | -$2.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kodiak Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.40% |
| Shareholder Yield | -5.40% |
| Earnings Yield | -10.21% |
| FCF Yield | -6.55% |
Analyst Forecast
The average price target for Kodiak Sciences is $62.67, which is 73.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $62.67 |
| Price Target Difference | 73.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
